Intraoperative methylene blue infusion reduces postoperative delirium in patients undergoing pancreatic surgery: A randomized controlled clinical trial (2025)

Peer-Reviewed Study · Deng Y, Dong J, Pan C, Deng L, He Z, Yang L, Hua J, Zhang J · November 1, 2025

Deng Y et al., 2025-11-01: HUMAN randomized single-blind trial in 314 pancreatic-surgery patients: intraoperative MB (2 mg/kg then 1 mg/kg) lowered delirium (11.5% vs 23.6%) with lower postoperative IL-6.

with a lower POD incidence in the methylene blue group than in the control group (11.5% vs. 23.6%, p = 0.005)

Deng Y et al., 2025-11-01: HUMAN randomized single-blind trial in 314 pancreatic-surgery patients: intraoperative MB (2 mg/kg then 1 mg/kg) lowered delirium (11.5% vs 23.6%) with lower postoperative IL-6. HUMAN, randomized, single-blind, single-centre (Fudan University Shanghai Cancer Center), n=314. Dose 2 mg/kg IV over 60 min after induction + 1 mg/kg IV over 30 min before end of surgery. Comparator: equal-volume saline. Authors declare no conflicts of interest (abstract). Funder not stated in abstract. Perioperative delirium endpoint only; no neurodegeneration outcome. Study type: randomized trial.